Amylyx Pharmaceuticals Faces Existential Crisis After Clinical Setbacks

Amylyx Pharmaceuticals finds itself in a fight for survival following the complete collapse of its flagship therapy and severe clinical disappointments. The biotechnology firm’s shares have plummeted to their lowest levels since the company’s initial public offering, with investors questioning its long-term viability.

Financial Position Shows Mixed Signals Amid Cash Concerns

The company’s second quarter 2025 financial results revealed both improvements and alarming vulnerabilities. While Amylyx managed to reduce its net loss significantly to $41.4 million ($0.46 per share), representing a 43.1% improvement year-over-year, underlying challenges paint a concerning picture:

• Cash reserves: $180.8 million (as of June 30, 2025)
• Concerning burn rate: $202 million consumed over the previous year
• Limited runway: Approximately 11 months of operational funding remaining

This financial cushion falls substantially short of management’s previous projection of sustainability through late 2026. The company’s spending patterns show a strategic shift, with SG&A expenses declining by 27.8% while research and development costs increased by 16.7% to $27.2 million, indicating a heightened focus on clinical programs.

Clinical Programs Face Devastating Blows

Amylyx’s research pipeline suffered catastrophic setbacks that have fundamentally shaken investor confidence. The company recently discontinued its ORION program evaluating AMX0035 for Progressive Supranuclear Palsy after the phase 2b trial failed to meet any primary or secondary endpoints over 24 weeks.

In a further devastating development, the U.S. Food and Drug Administration (FDA) formally withdrew approval for Relyvrio, Amylyx’s treatment for amyotrophic lateral sclerosis (ALS). This action came at the company’s own request following the therapy’s failure in a crucial phase 3 study. The product had already been withdrawn from U.S. and Canadian markets earlier in 2024.

Should investors sell immediately? Or is it worth buying Amylyx Pharmaceuticals?

Strategic Pivot to Avexitide as Final Hope

In response to these clinical failures, Amylyx has declared its GLP-1 receptor antagonist, avexitide, as its new highest priority. The drug candidate currently occupies the spotlight as the company’s most promising asset, carrying both FDA Breakthrough Therapy and Orphan Drug designations for the treatment of post-bariatric hypoglycemia.

Key milestones for avexitide include:

• Trial completion: Enrollment expected to conclude during 2025
• Data readout: Topline results anticipated in the first half of 2026
• Potential approval: Possible market launch in 2027

The ongoing pivotal phase 3 LUCIDITY study will determine whether this single therapy can potentially support the company’s entire market valuation.

Survival Hinges on Critical Timing Questions

Amylyx has executed a complete strategic realignment, shifting focus to avexitide alongside niche programs including AMX0035 for Wolfram syndrome and AMX0114 for ALS. Management faces intense scrutiny, with recent presentations at financial conferences like the Citi event serving as crucial tests of leadership credibility.

The central question confronting investors remains whether current financial resources will sustain operations until avexitide data becomes available in mid-2026, or if Amylyx must pursue dilutive financing options in the near term. Shareholders now face a period of significant uncertainty as the company’s future hangs in the balance.